Is GRAL a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Galleri volume and revenue growth, with revenue (ttm) at ~$165M. The bear case rests on gRAIL is unprofitable, posting a net loss of about $110 million in Q2 2026 and a trailing-twelve-month loss near $392 million, so it depends on its cash balance and eventual funding rather than current earnings. Analysts covering it are spread from $74.00 to $180.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. GRAIL is unprofitable, posting a net loss of about $110 million in Q2 2026 and a trailing-twelve-month loss near $392 million, so it depends on its cash balance and eventual funding rather than current earnings. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $74.00, -37.2% from the $117.81 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Galleri volume and revenue growth. Galleri test volume grew roughly 50% year over year in Q1 2026 to more than 56,000 tests, and total revenue rose about 26% to roughly $44.7 million in Q2 2026. The most optimistic analyst target on GRAL is $180.00, +52.8% from the $117.81 price. That figure is only reachable if this thesis works close to its best case.

GRAIL is unprofitable, posting a net loss of about $110 million in Q2 2026 and a trailing-twelve-month loss near $392 million, so it depends on its cash balance and eventual funding rather than current earnings. The business is concentrated in essentially one product, Galleri, which leaves it exposed to any single negative FDA, clinical, or reimbursement outcome; a favorable advisory panel does not guarantee approval or a particular label. Even with approval, the reimbursement price insurers will pay against today's $949 list price is a key unknown. Competition in multi-cancer detection is intensifying from Exact Sciences (Cancerguard), Guardant Health (Shield), Freenome, and others. Cash burn is heavy (operating cash flow was roughly negative $295 million over the trailing year), and delays could force a capital raise that dilutes shareholders. After rallying about 70% in three months, the stock trades at about 33x trailing sales, insiders have sold shares in October 2026, and some commentators have called it too expensive to chase, so volatility in both directions is likely. The most pessimistic published target is $74.00, -37.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Galleri volume and revenue growth) stalling in the reported numbers rather than in the narrative, the risk above (gRAIL is unprofitable, posting a net loss of about $110 million in Q2 2026 and a trailing-twelve-month loss near $392 million, so it depends on its cash balance and eventual funding rather than current earnings) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

GRAIL sells the Galleri multi-cancer early detection test, a blood draw that screens for DNA shed by tumors to detect many types of cancer at once, including cancers that currently have no routine screening. It is a commercial-stage diagnostics company, not a therapeutics maker.

No. GRAIL generates real and growing revenue from Galleri but runs large losses, with a net loss of about $110 million in Q2 2026 and about $392 million over the trailing twelve months as it funds commercial scale-up and clinical trials. Losses per share have been narrower than analysts expected, but low profitability is normal for a company at this stage.

Trailing-twelve-month revenue is roughly $165 million as of mid-2026, with Q2 2026 revenue near $44.7 million, up about 26% year over year. Most of that comes from the Galleri test, whose volumes grew around 50% year over year in Q1 2026. Analysts expect about $181 million for full-year 2026.